GBE1 and disorder of glycogen metabolism: Since all GSDs share the etiology of excessive normal or malconstructed glycogen, we believe that APBD represents a prototypical GSD and thus development of pharmaceutical inhibitors of glycogen accumulation is likely to benefit all GSDs (except for GSD0, where glycogen deficiency, rather than surplus, is considered the pathogenic factor (Orho et al, 1998)).